Akebia Therapeutics | AKBA - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Ardelyx USD 120.12M 14.46M 2025-12
Astellas Pharma JPY 489.36B 52.69B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Bayer EUR 9.88B 452M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Celltrion KRW 140.68B 584.31B 2025-12
Cspc Pharmaceutical CNY 5.91B 512.77M 2025-12
Deva Holding AS TRY 1.35B 178.26M 2023-09
Dianthus Therapeutics USD 69.82M 29.14M 2025-12
Exelixis USD 359.47M 3.28M 2026-03
Fresenius Medical Care EUR 4.34B 63M 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 17.44B 1.53B 2026-03
Kangmei Pharma CNY 1.39B 144.29M 2025-09
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Laboratorios Farma EUR 313.62M 17.98M 2023-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 21.61M 11.59M 2025-12
Moderna USD 1.78B 242M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neuren Pharmaceuticals AUD 25.23M 16.54M 2025-12
Organigram Holdings CAD 83.66M 24.44M 2025-12
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pharma Mar EUR 42.28M 4.59M 2026-03
Prothena USD 27.23M 14.95M 2025-12
PTC Therapeutics USD 226.66M 19.64M 2026-03
Qiagen NV USD 418.54M 23.25M 2025-12
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Sartorius EUR 738.4M 22.4M 2026-03
Sino Biopharmaceutical CNY 12.39B 1.26B 2025-06
Tectonic Therapeutic USD 21.52M 374K 2025-12
Tilray USD 237.52M 17.34M 2025-09
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Zealand Pharma A/S 775.97M 265.08M 2025-12
Zz Pientze Pharmaceu CNY 1.88B 326.34M 2026-03